Related Experiment Video
Updated: Jun 30, 2026
08:54
Human In-Vivo Bioassay for the Tissue-Specific Measurement of Nociceptive and Inflammatory Mediators
Published on: December 1, 2008
10.3K
Self-assembling Organogels Loaded with Tenoxicam for Local Intensive Pain and Inflammation Cure: In Vitro and In Vivo
Shaaban K Osman1, Taher M Yassin2, Arafat Abdelzaher3
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, 71524, Egypt. shaabanosman@azhar.edu.eg.
AAPS Pharmscitech
|January 23, 2024
Summary
New pluronic/lecithin organogels (PLOs) offer improved topical delivery for tenoxicam (TX). These gels bypass gastrointestinal issues, showing significant anti-inflammatory and analgesic effects in vivo with sustained drug release.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Materials Science
Background:
- Tenoxicam (TX) exhibits poor aqueous solubility, limiting its oral absorption and potentially causing gastrointestinal disturbances.
- Topical administration of tenoxicam presents an alternative route to mitigate systemic side effects associated with oral delivery.
Purpose of the Study:
- To develop and characterize pluronic/lecithin organogels (PLOs) for enhanced topical delivery of tenoxicam.
- To evaluate the physicochemical properties, in vitro drug release kinetics, and in vivo anti-inflammatory and analgesic efficacy of the developed PLOs.
Main Methods:
- Pluronic/lecithin organogels (PLOs) were formulated by direct mixing of pluronic and lecithin solutions.
- Physicochemical characterization included pH, drug content, visual inspection, viscosity, and spreadability assessments.
- In vitro drug release studies and kinetic analysis were performed, followed by in vivo anti-inflammatory and analgesic evaluations in albino male rats.
Main Results:
- The modified PLOs demonstrated favorable physicochemical properties, with viscosity directly correlating to lecithin and pluronic concentrations.
- Drug release rate was found to be directly proportional to the gel viscosity.
- The optimized PLO formulation (F19) exhibited significant paw edema inhibition and pain analgesia (p < 0.05%) compared to control groups, with effects sustained up to 12 hours.
Conclusions:
- Modified pluronic/lecithin organogels are effective vehicles for topical tenoxicam delivery.
- These PLOs offer a promising, safe alternative for loading tenoxicam, providing sustained drug release and enhanced therapeutic effects.
- The developed topical delivery system successfully overcomes the limitations of oral tenoxicam administration.
Related Concept Videos
01:44Nociception
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
01:30Local Anesthetics: Chemistry and Structure-Activity Relationship
Local anesthetics (LAs) are drugs that induce a temporary loss of sensation in a limited body area, preventing pain. Cocaine was the first local anesthetic discovered in the late 19th century. Cocaine is a benzoic acid ester obtained from the leaves of coca shrubs and was often used for its psychotropic effects. Cocaine was first isolated in 1860 by Albert Niemann. Sigmund Freud studied the physiological actions of cocaine. Carl Koller later introduced it into clinical practice in 1884 as a...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...